YAP1 and sarcoma: Furthermore, a study encompassing an immunohistochemistry (IHQ) assessment of TAZ and YAP in 159 sarcomas representing the most prevalent types showed that 50% and 66% of samples exhibit activation (or nuclear location) of YAP and TAZ, respectively [67].